On February 16, 2021 Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, reported that it is presenting at the BIO CEO & Investor Digital Conference, 16-18th February 2021 (Press release, Tiziana Life Sciences, FEB 16, 2021, View Source [SID1234575110]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences, commented, "I look forward to sharing our exciting story with conference attendees. With the release of our topline data from our COVID-19 trial, multiple Phase 2 trial launches expected in 2021, and the potential application of Foralumab in a wide range of autoimmune and inflammatory diseases in the longer-term, we are well positioned to achieve a series of important milestones in the months and quarters ahead."

Tiziana Life Sciences presentation will be accessible on demand during the virtual event for all registered attendees.

On February 16, 2021 HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, reported that it has raised an additional $3M as part of a seed financing round led by Zoic Capital for a total seed-stage raise of $6M (Press release, HDT Bio, FEB 16, 2021, View Source [SID1234575109]). The funding will support advancing HDT Bio’s three lead products into clinical trials this year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HDT Bio CEO Steven Reed said, "These funds will keep us on track to move into the clinic with products from all three of our immune activator platform technologies. We are excited to close our seed round and to move forward with clinical development."

Neal Mody, Managing Director at Zoic Capital, commented, "This is a milestone year for HDT Bio as it transitions into clinical development with multiple assets and numerous market opportunities worldwide."

HDT three lead products are:

HDT-301, a COVID-19 RNA vaccine which uses the company’s proprietary Lipid InOrganic Nanoparticle (LION) formulation to offer simpler and cheaper manufacturing, easier deployment, and vastly lower dosing than current mRNA vaccines.

HDT-201, a RIG-I immune-stimulating protein which improves the effectiveness of immuno-oncology drugs such as checkpoint inhibitors.

HDT-104, a protein that breaks down structural defenses erected by epithelial tumors, making cancers more responsive to treatment through immunotherapy and chemotherapy.

Since its founding in 2017, HDT Bio has raised a total of $16M through a combination of non-dilutive funding, international grants, private investment, and partnership revenue.

On February 16, 2021 Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, reported that IgEs and their potential as "a great way for targeting cancer cells for killing" were cited in a Technology Feature article in the leading science journal, Nature (Press release, Epsilogen, FEB 16, 2021, View Source [SID1234575108]). Entitled "Seven technologies to watch in 2021", the article provided views from seven leading researchers from across the life sciences. Alicia Chenoweth, cancer immunologist at King’s College London and co-chair of the 2022 Antibody Biology and Engineering Gordon Research Conference, exemplified IgEs in her section outlining emerging antibody engineering technologies that she believes could have a significant impact on science in the coming year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Epsilogen is a pioneer of novel modified IgE antibodies, which have great potential to treat solid cancer tumours. The company is progressing its lead product, MOv18 IgE, towards phase I/IIa clinical trials for the treatment of platinum-resistant ovarian cancer. Phase I data showing safety and initial signs of efficacy of MOv18 IgE in these patients was presented at the 2020 AACR (Free AACR Whitepaper) Virtual Annual Meeting in April.

Dr Tim Wilson, Chief Executive Officer of Epsilogen, commented: "We are pleased to see IgE antibodies recognised in a leading scientific journal as one of the most promising emerging technologies across the entire life sciences sector."

On February 16, 2021 Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, reported the company’s participation at upcoming healthcare investor conferences (Press release, Arch Oncology, FEB 16, 2021, View Source;utm_medium=rss&utm_campaign=arch-oncology-to-participate-in-upcoming-conferences [SID1234575107]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: SVB Leerink 9th Annual Healthcare Conference
Date: February 23, 2021

Event: Oppenheimer’s 31st Annual Healthcare Conference
Date: March 16, 2021, 4:30 – 5:00 pm ET

On February 16, 2021 Perrigo Company plc (NYSE; TASE: PRGO) reported that it will release its fourth quarter and calendar year 2020 financial results on Monday, March 1, 2021 (Press release, Perrigo Company, FEB 16, 2021, View Source [SID1234575106]). The Company will also host a conference call beginning at 8:00 a.m. (EST).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at View Source or by phone at 888-317-6003, International 412-317-6061, and reference ID # 6715549. A taped replay of the call will be available beginning at approximately 12:00 p.m. (EST) Monday, March 1, until midnight Monday, March 15, 2021. To listen to the replay, dial 877-344-7529, International 412-317-0088, and use access code 10152495.